Eli Lilly And Co (LLY) Position Lifted by BB&T Securities LLC

BB&T Securities LLC increased its position in Eli Lilly And Co (NYSE:LLY) by 1.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 158,825 shares of the company’s stock after buying an additional 2,101 shares during the period. BB&T Securities LLC’s holdings in Eli Lilly And Co were worth $18,378,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of LLY. State of Alaska Department of Revenue lifted its stake in Eli Lilly And Co by 3.3% in the 4th quarter. State of Alaska Department of Revenue now owns 204,487 shares of the company’s stock worth $23,660,000 after purchasing an additional 6,474 shares in the last quarter. Arizona State Retirement System lifted its stake in Eli Lilly And Co by 0.8% in the 3rd quarter. Arizona State Retirement System now owns 278,567 shares of the company’s stock worth $29,893,000 after purchasing an additional 2,174 shares in the last quarter. Balasa Dinverno & Foltz LLC lifted its stake in Eli Lilly And Co by 15.9% in the 3rd quarter. Balasa Dinverno & Foltz LLC now owns 3,629 shares of the company’s stock worth $389,000 after purchasing an additional 499 shares in the last quarter. Pennsylvania Trust Co lifted its stake in Eli Lilly And Co by 46.4% in the 4th quarter. Pennsylvania Trust Co now owns 85,021 shares of the company’s stock worth $9,839,000 after purchasing an additional 26,947 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its stake in Eli Lilly And Co by 0.7% in the 3rd quarter. Macquarie Group Ltd. now owns 321,764 shares of the company’s stock worth $34,527,000 after purchasing an additional 2,367 shares in the last quarter. 80.84% of the stock is owned by institutional investors.

Shares of NYSE LLY opened at $119.65 on Thursday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91. The stock has a market cap of $125.67 billion, a PE ratio of 21.56, a price-to-earnings-growth ratio of 1.91 and a beta of 0.37. Eli Lilly And Co has a 12-month low of $74.51 and a 12-month high of $121.84.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.36 by ($0.03). The business had revenue of $6.44 billion for the quarter, compared to analysts’ expectations of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 42.55%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.14 earnings per share. As a group, sell-side analysts expect that Eli Lilly And Co will post 5.6 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be given a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a dividend yield of 2.16%. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date is Thursday, February 14th. Eli Lilly And Co’s dividend payout ratio is currently 40.54%.

Several analysts have commented on the stock. Cantor Fitzgerald reiterated a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. Citigroup cut shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $113.00 price target on the stock. in a research note on Sunday, December 2nd. Zacks Investment Research cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday, December 4th. UBS Group decreased their price target on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research note on Friday, February 8th. Finally, Barclays reiterated a “buy” rating and issued a $130.00 price target on shares of Eli Lilly And Co in a research note on Sunday, January 20th. Eleven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Eli Lilly And Co has a consensus rating of “Buy” and a consensus target price of $111.41.

In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $113.74, for a total transaction of $22,748,000.00. Following the sale, the insider now directly owns 118,600,804 shares in the company, valued at approximately $13,489,655,446.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 4,000 shares of the company’s stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $120.00, for a total transaction of $480,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 817,843 shares of company stock worth $94,595,335 over the last 90 days. Corporate insiders own 0.11% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Eli Lilly And Co (LLY) Position Lifted by BB&T Securities LLC” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.chaffeybreeze.com/2019/02/14/eli-lilly-and-co-lly-position-lifted-by-bbt-securities-llc.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Quiet Period Expirations

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply